ach year, Digestive Disease Week® (DDW) brings together the best clinical, translational, and basic science in the field. It is also an opportunity for many trainees and young investigators to present their work, receive advice from senior investigators, and build their professional networks. At DDW 2018, the American Gastroenterological Association (AGA) recognized 1 member each from 13 Council sections who have committed themselves to training these young investigators and have a demonstrated track record of outstanding research mentorship. Cellular Molecular Gastroenterology and Hepatology extends our appreciation to the awardees in each section for providing guidance and mentorship to the next generation of researchers.
Basic and Clinical Intestinal Disorders Section: Gary D. Wu, MD
Gary Wu is the Ferdinand G. Weisbrod Professor in Gastroenterology at the University of Pennsylvania's Perelman School of Medicine where he is the GI Associate Chief for Research, the Associate Director of the Center for Molecular Studies in Digestive and Liver Disease, the Co-Director of the PennCHOP Microbiome Program, and the Director of the Penn Center for Nutritional Sciences and Medicine. With respect to the latter, he is an advisor to the National Institutes of Health (NIH), the National Academy of Sciences, and the US Department of Agriculture on topics related to human health, diet, and nutrition. An elected member of both the American Society for Clinical Investigation and the Association of American Physicians, Dr Wu was the inaugural Director and Chair of the Scientific Advisory Board for the AGA's Center for Gut Microbiome Research and Education and currently serves as the Basic Research Councillor of AGA's Governing Board. Research programs in the Wu laboratory focus on the mutualistic interactions between the gut microbiota and its host, with a particular emphasis on metabolism including nitrogen balance, intestinal oxygen regulation, and epithelial intermediary metabolism. As a physician-scientist, he has gained international recognition for his highly innovative multidisciplinary team research approach to translational avenues of investigation that help to guide the development of therapeutic strategies relevant to inflammatory bowel disease (IBD) and metabolic diseases. Dr Wu has been a mentor to dozens of graduate students, postdoctoral students, and medical students, and has specifically mentored 11 gastroenterology fellows, nearly all of whom remain actively involved in research at academic medical centers and in industry. Dr Burt is a clinical genetics investigator (gastroenterologist) whose career has involved research in the inheritance of colorectal cancer and the identification of colon cancer susceptibility genes. He was one of the first investigators to describe common inheritance of colonic adenomatous polyps segregating with colorectal cancer. He was involved with identifying the APC gene, describing the attenuated polyposis syndrome, developing strategies for genetic testing and surveillance for inherited and familial high-risk colon cancer, and performing clinical trials for chemoprevention in sporadic and inherited colon cancer. He also has studied genetic-environmental interactions and gene-gene interactions of colon cancer. His clinical focus is screening for colorectal and other cancers, with particular attention given to increased risk factors in inherited and noninherited polyposis syndromes. Dr Burt has been a principal investigator on several large NIH studies of colon cancer, and has authored or co-authored numerous textbook chapters and articles in major scientific journals, several of which are considered seminal. These activities has involved trainee and faculty mentoring. Continuously funded since that time, her laboratory has contributed substantially to our understanding of the molecular and cellular mechanisms of intestinal development, villus morphogenesis, and intestinal elongation. Her laboratory developed tools for the analysis of intestinal development and homeostasis that have enabled hundreds of investigators across the world to modify gene expression in the intestinal epithelium (the Villin promoter, now at AddGene and the Villin-Cre mice, at Jackson Laboratories). Dr Gumucio has trained 26 graduate students and postdoctoral fellows, many of whom have gone on to contribute to the scientific community. In 1995, Dr Gumucio founded the Center for Organogenesis at Michigan (and served as its Director until 2010); this cross-disciplinary center continues to promote interactions among applied, clinical, and basic scientists focused on organ development and disease. In addition, she directed the Organogenesis Training Program (T32 funded) and pioneered the BioArtography Project, a blend of art and science that serves as a public outreach program and fundraiser for trainees at Michigan (www.bioartography.com). Dr Wallace has published more than 300 peer-reviewed manuscripts and more than 300 abstracts, book chapters, review articles, and editorials. He has mentored more than 30 gastroenterology and research fellows from around the world, many of whom have gone on to distinguished careers themselves. Pathology and a Professor of Pediatrics at the same university since 1994 and 1997, respectively. His lifelong research interest is the pathogenesis of inflammatory bowel disease, in which he has made numerous contributions in the areas of immunoregulation, cytokines, immune-nonimmune cell interactions, angiogenesis, fibrosis, and pediatric IBD. His most recent area of interest is the use of systems biology to understand IBD pathogenesis in a more comprehensive fashion. During his career, Dr Fiocchi was privileged in training several young investigators from the United States, Europe, Asia, and South America, many of whom went on to become leaders in IBD in their own countries.
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In addition, he has served as an Associate Editor or Editorial Board member of several journals including Gastroenterology, Inflammatory Bowel Diseases, Digestive and Liver Disease, Current Opinion in Gastroenterology, and the American Journal of Physiology Gastrointestinal and Liver Physiology.
Liver and Biliary Section: Scott L. Friedman, MD Scott L. Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. He has performed pioneering research into the underlying causes of scarring, or fibrosis associated with chronic liver disease, affecting millions worldwide. Dr Friedman was among the first to isolate and characterize the hepatic stellate cell, the key cell type responsible for scar production in the liver. His work has spawned an entire field that now is realizing its translational and therapeutic potential, with new antifibrotic therapies for liver disease reaching clinical trials. Dr Friedman's work has been continuously funded by the NIH since 1985.
A 1979 graduate of the Icahn School of Medicine at Mount Sinai, he was a Medical Resident at Beth Israel Hospital in Boston, followed by a Gastroenterology Fellowship at the University of California San Francisco before assuming a faculty position there, which he held for 10 years. He is widely recognized as a dynamic effective speaker, and is also a respected author, with more than 350 peer-reviewed publications. Dr Friedman was a recipient in 1993 of the Saul Horowitz, Jr, Outstanding Alumnus Award from Mount Sinai. In 2003, Dr Friedman was honored with the International Hans Popper Award for his outstanding contributions to the understanding of liver disease and its treatment. He has mentored more than 80 postdoctoral fellows and students, most of whom remain in academic training programs or faculty. Members of his laboratory have developed gnotobiotic animal models, and new experimental and computational approaches to characterize the assembly, dynamic operations, functional properties, and biological effects of human gut microbial communities. He has combined these models with human studies involving twins as well as members of birth cohorts living in low-, middle-, and high-income countries representing diverse geographic locations and cultural traditions. His group is focused on addressing the global health challenges of obesity and childhood undernutrition through new understanding of the interactions between diets and the gut microbiome and new ways of promoting healthy development of the gut community during the first several years of postnatal life.
He regards his greatest honor as having had the privilege and pleasure of serving as the research mentor to more than 130 PhD and MD/PhD students and postdoctoral fellows, a number of whom have become leaders in the microbiome field. Dr McCallum has made major advances in pathophysiology, diagnosis and treatment of gastrointestinal motility disorders and functional bowel problems, specifically gastroparesis, the interactions between the brain and the gut, as well as the mechanisms of nausea and vomiting. He pioneered gastric electrophysiology in humans and is the inventor of a gastric pacemaker for treating gastroparesis. His research has been funded by the VA, American Diabetes Association, pharmaceutical support, and the NIH, where he is a member of the NIH Clinical Research Consortium in Gastroparesis, now funded for the past 12 years. He has more than 480 peerreviewed scientific articles and 130 textbook chapters and has edited 15 scientific textbooks. He has mentored more than 100 US and international research trainees, many of whom are now academic leaders including Dr Barry Marshall, the 2005 Nobel Prize winner for the discovery of H pylori causing peptic ulcer.
Neurogastroenterology
Obesity, Metabolism, and Nutrition Section: Lee M. Kaplan, MD, PhD, AGAF
